Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 2/20 | 0.88 |
| ▸ | SELPLG | Q14242 | 1/20 | 0.88 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12216369 | 0.97 | SELP (0.90) | SELPSELPLGPPARGPPARDPPARA | |
| SCHEMBL13390070 | 0.96 | SELP (0.91) | SELPSELPLGPPARGPPARDPPARA | |
| SCHEMBL8205205 | 0.94 | SELP (0.98) | SELPSELPLGPPARGPPARDPPARA | |
| SCHEMBL7619803 | 0.94 | SELP (0.98) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL14015902 | 0.94 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL2529148 | 0.94 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| SCHEMBL7614341 | 0.94 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| SCHEMBL7620761 | 0.94 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL12182030 | 0.94 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA | |
| Bimosiamose SCHEMBL29367817 | 0.94 | SELP (1.00) | SELPSELPLGPPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298245-A1 | Pharmaceutical Composition for the Treatment of IL-8 mediated diseases | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20100298245-A1 | Pharmaceutical Composition for the Treatment of IL-8 mediated diseases | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298245-A1 | Pharmaceutical Composition for the Treatment of IL-8 mediated diseases | CXCL8, IL18, IL1B | SELP 191/4885SELPLG 303/4885PPARG 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.